Altimmune Inc (ALT) Stock Price, Quote & News

Company Profile

Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

Industry: Biotechnology

Sector: Healthcare

Phone: 240 654 1450

Website: altimmune.com

Address:

910 Clopper Road, Suite 201S, Gaithersburg, United States

Babybock Apr. 27 at 10:32 AM

$ALT grabbing a few this morning to start my week off on the right foot.

0 · Reply

saad545 Apr. 27 at 10:31 AM

$ALT we will stay here until you cover and lose your money⬆️🔥

0 · Reply

GreenEnergy2022 Apr. 27 at 10:05 AM

$ALT Stocks goes up and down, 2,8 is not the end of the story here. Now we buy, and then we wait. Simplest thing in life

0 · Reply

lottomillions Apr. 27 at 10:05 AM

$ALT @Turribull You have by your own admission had a 5-7B target on this for the 16th of April. Only off by a breathtakingly bad 1000%. Those naive enough to listen to you have lost enough. Have a little bit of reflection on the damage you did to those peoples portfolios with the relentless promotion campaign.

0 · Reply

OutlawBikerRR Apr. 27 at 9:52 AM

$ALT ARE WE HAPPY FOR 2.88$ ??

0 · Reply

Babybock Apr. 27 at 9:29 AM

$ALT

0 · Reply

AF5 Apr. 27 at 9:04 AM

$ALT

0 · Reply

PrecisionGuidanceNetwork Apr. 27 at 8:48 AM

$ALT biotech with sharp catalyst-driven volatility around major updates

0 · Reply

DragonAlgo Apr. 27 at 8:44 AM

🐉 $ALT PUT — DragonAlgo® Signal Contract: ALT PUT Expiry: 2026-05-01 | Strike: $3.00 | Type: PUT Option Plan (premium): Entry: $0.20 Stop: $0.14 TP1: $0.26 TP2: $0.34 TP3: $0.48 Momentum tape remains active. 🔗 https://dragonalgo.com

0 · Reply

Rich1979 Apr. 27 at 7:41 AM

$ALT

0 · Reply

Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of Securities

Apr 22, 2026, 4:19 PM EDT - 4 days ago

Altimmune Announces Proposed Underwritten Public Offering of Securities

Apr 16, 2026, 8:30 AM EDT - 10 days ago

Altimmune Transcript: AGM 2026

Mar 12, 2026, 10:30 AM EDT - 6 weeks ago

Altimmune Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 11, 2026, 9:20 AM EDT - 6 weeks ago

Altimmune Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 2:15 PM EDT - 6 weeks ago

Altimmune Transcript: The Citizens Life Sciences Conference 2026

Mar 5, 2026, 8:30 AM EST - 7 weeks ago

Altimmune Earnings Call Transcript: Q4 2025

Mar 5, 2026, 7:00 AM EST - 7 weeks ago

Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates

Mar 2, 2026, 7:30 AM EST - 7 weeks ago

Altimmune to Participate in Upcoming Investor Conferences

Feb 26, 2026, 7:30 AM EST - 2 months ago

Altimmune to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026

Feb 3, 2026, 1:27 PM EST - 2 months ago

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

AMGN GPCR LLY NVO PFE VKTX

Jan 29, 2026, 5:54 PM EST - 3 months ago

Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock

Jan 28, 2026, 4:13 PM EST - 3 months ago

Altimmune (ALT) Shares Slide On $75 Million Stock Offering

Jan 27, 2026, 9:25 PM EST - 3 months ago

Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock

Jan 5, 2026, 7:30 AM EST - 3 months ago

Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH

Dec 19, 2025, 12:57 PM EST - 4 months ago

Altimmune's MASH Drug Shows Durable Liver, Weight Loss Gains At 48 Weeks

Dec 19, 2025, 8:00 AM EST - 4 months ago

Altimmune Transcript: Study Result

Dec 19, 2025, 6:42 AM EST - 4 months ago

Altimmune's drug for a type of liver disease shows benefits in mid-stage study

Dec 19, 2025, 6:30 AM EST - 4 months ago

Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial

Dec 3, 2025, 2:30 PM EST - 5 months ago

Altimmune Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 1, 2025, 7:30 AM EST - 5 months ago

Altimmune Announces CEO Transition and Succession Plan

Nov 26, 2025, 7:30 AM EST - 5 months ago

Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 20, 2025, 3:00 AM EST - 5 months ago

Altimmune Transcript: Jefferies London Healthcare Conference 2025

Nov 12, 2025, 10:00 AM EST - 5 months ago

Altimmune Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 8:51 AM EST - 5 months ago

Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025

Nov 7, 2025, 8:05 AM EST - 6 months ago

Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025

Nov 6, 2025, 8:30 AM EST - 6 months ago

Altimmune Earnings Call Transcript: Q3 2025

Nov 6, 2025, 7:00 AM EST - 6 months ago

Altimmune Announces Third Quarter 2025 Financial Results and Business Updates

Nov 5, 2025, 7:30 AM EST - 6 months ago

Altimmune to Participate in Two Upcoming Investor Conferences

Nov 3, 2025, 7:30 AM EST - 6 months ago

Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder

Oct 30, 2025, 7:30 AM EDT - 6 months ago

Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025

Oct 21, 2025, 7:00 AM EDT - 6 months ago

Altimmune Transcript: H.C. Wainwright Liver Disease Virtual Conference

Oct 20, 2025, 7:30 AM EDT - 6 months ago

Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting® 2025

Oct 6, 2025, 10:09 AM EDT - 7 months ago

ALTIMMUNE FINAL DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Urges Investors to Contact the Firm Regarding the October 6th Deadline

Oct 5, 2025, 11:40 PM EDT - 7 months ago

ALT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Oct 3, 2025, 9:50 AM EDT - 7 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Sep 30, 2025, 10:30 AM EDT - 7 months ago

Altimmune Transcript: Stifel Virtual Cardiometabolic Forum

Sep 30, 2025, 10:20 AM EDT - 7 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Sep 29, 2025, 7:30 AM EDT - 7 months ago

Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide

Sep 25, 2025, 8:30 AM EDT - 7 months ago

Altimmune Transcript: AGM 2025

Sep 21, 2025, 8:39 AM EDT - 7 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Sep 19, 2025, 10:27 AM EDT - 7 months ago

Bragar Eagel & Squire, P.C. Reminds Investors of Altimmune and SelectQuote that Lawsuits Have Been Filed and Encourages Investors to Contact the Firm

SLQT

Sep 18, 2025, 8:45 AM EDT - 7 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of October 6, 2025 in Altimmune, Inc. Lawsuit - ALT

Sep 15, 2025, 7:30 AM EDT - 7 months ago

Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer

Sep 10, 2025, 7:45 AM EDT - 8 months ago

Altimmune Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 9, 2025, 8:30 AM EDT - 8 months ago

Altimmune Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Aug 19, 2025, 7:30 AM EDT - 8 months ago

Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD)

Aug 15, 2025, 12:06 PM EDT - 9 months ago

Berger Montague PC Investigates Securities Claims Against Altimmune, Inc. (NASDAQ: ALT)

Aug 13, 2025, 2:57 PM EDT - 9 months ago

These Analysts Slash Their Forecasts On Altimmune Following Q2 Results

Aug 12, 2025, 8:30 AM EDT - 9 months ago

Altimmune Earnings Call Transcript: Q2 2025

Jun 26, 2025, 8:30 AM EDT - 10 months ago

Altimmune Transcript: Study Result

Jun 4, 2025, 9:55 AM EDT - 11 months ago

Altimmune Transcript: Jefferies Global Healthcare Conference 2025

May 20, 2025, 10:00 AM EDT - 1 year ago

Altimmune Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 13, 2025, 8:30 AM EDT - 1 year ago

Altimmune Earnings Call Transcript: Q1 2025

May 7, 2025, 9:30 AM EDT - 1 year ago

Altimmune Transcript: The Citizens JMP Life Sciences Conference 2025

Mar 13, 2025, 12:00 PM EDT - 1 year ago

Altimmune Transcript: R&D Day 2025

Mar 10, 2025, 3:40 PM EDT - 1 year ago

Altimmune Transcript: Leerink’s Global Healthcare Conference 2025

Feb 27, 2025, 8:30 AM EST - 1 year ago

Altimmune Earnings Call Transcript: Q4 2024

Feb 5, 2025, 9:30 AM EST - 1 year ago

Altimmune Transcript: Guggenheim SMID Cap Biotech Conference

Dec 4, 2024, 3:30 PM EST - 1 year ago

Altimmune Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 3, 2024, 10:50 AM EST - 1 year ago

Altimmune Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Nov 13, 2024, 12:30 PM EST - 1 year ago

Altimmune Transcript: UBS Global Healthcare Conference 2024

Nov 12, 2024, 8:30 AM EST - 1 year ago

Altimmune Earnings Call Transcript: Q3 2024

Nov 11, 2024, 11:30 AM EST - 1 year ago

Altimmune Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Oct 7, 2024, 11:30 AM EDT - 1 year ago

Altimmune Transcript: 8th Annual MASH Investor Conference

Aug 8, 2024, 8:30 AM EDT - 1 year ago

Altimmune Earnings Call Transcript: Q2 2024

Jun 12, 2024, 9:20 AM EDT - 2 years ago

Altimmune Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 5, 2024, 2:00 PM EDT - 2 years ago

Altimmune Transcript: Jefferies 2024 Global Healthcare Conference

May 23, 2024, 10:00 AM EDT - 2 years ago

Altimmune Transcript: UBS Obesity Therapeutics Day

May 14, 2024, 9:00 AM EDT - 2 years ago

Altimmune Transcript: The Citizens JMP Life Sciences Conference

May 9, 2024, 8:30 AM EDT - 2 years ago

Altimmune Earnings Call Transcript: Q1 2024

Mar 27, 2024, 8:30 AM EDT - 2 years ago

Altimmune Earnings Call Transcript: Q4 2023

Dec 1, 2023, 8:30 AM EST - 2 years ago

Altimmune Transcript: Study Result

Nov 7, 2023, 8:30 AM EST - 2 years ago

Altimmune Earnings Call Transcript: Q3 2023

Sep 13, 2023, 1:35 PM EDT - 2 years ago

Altimmune Transcript: Morgan Stanley 21st Annual Global Healthcare Conference 2023

Sep 6, 2023, 3:45 PM EDT - 2 years ago

Altimmune Transcript: Wells Fargo Securities Healthcare Conference 2023

Aug 10, 2023, 8:30 AM EDT - 2 years ago

Altimmune Earnings Call Transcript: Q2 2023

Jun 14, 2023, 7:00 PM EDT - 3 years ago

Altimmune Transcript: Goldman Sachs 44th Annual Global Healthcare Conference

May 11, 2023, 8:30 AM EDT - 3 years ago

Altimmune Earnings Call Transcript: Q1 2023

Mar 21, 2023, 9:00 AM EDT - 3 years ago

Altimmune Transcript: Study Result

Feb 28, 2023, 8:30 AM EST - 3 years ago

Altimmune Earnings Call Transcript: Q4 2022

Dec 20, 2022, 8:00 AM EST - 3 years ago

Altimmune Transcript: Study Result

Nov 10, 2022, 11:00 AM EST - 3 years ago

Altimmune Earnings Call Transcript: Q3 2022

Sep 14, 2022, 8:30 AM EDT - 3 years ago

Altimmune Transcript: Study Result

Aug 11, 2022, 8:15 AM EDT - 4 years ago

Altimmune Earnings Call Transcript: Q2 2022

May 12, 2022, 2:30 PM EDT - 4 years ago

Altimmune Earnings Call Transcript: Q1 2022

Mar 15, 2022, 9:47 AM EDT - 4 years ago

Altimmune Earnings Call Transcript: Q4 2021

Nov 8, 2021, 7:00 PM EST - 4 years ago

Altimmune Earnings Call Transcript: Q3 2021

Sep 30, 2021, 9:00 AM EDT - 4 years ago

Altimmune Transcript: KOL Event

Sep 28, 2021, 8:30 AM EDT - 4 years ago

Altimmune Transcript: Study Result

Aug 11, 2021, 6:02 AM EDT - 5 years ago

Altimmune Earnings Call Transcript: Q2 2021

Jun 16, 2021, 8:30 AM EDT - 5 years ago

Altimmune Transcript: Study Update

May 17, 2021, 9:37 AM EDT - 5 years ago

Altimmune Earnings Call Transcript: Q1 2021

Feb 25, 2021, 8:30 AM EST - 5 years ago

Altimmune Earnings Call Transcript: Q4 2020

Nov 10, 2020, 8:30 AM EST - 5 years ago

Altimmune Earnings Call Transcript: Q3 2020

Sep 24, 2020, 10:00 AM EDT - 6 years ago

Altimmune Transcript: AGM 2020

Aug 12, 2020, 8:30 AM EDT - 6 years ago

Altimmune Earnings Call Transcript: Q2 2020

Jun 1, 2020, 8:30 AM EDT - 6 years ago

Altimmune Transcript: Status Update

May 14, 2020, 8:30 AM EDT - 6 years ago

Altimmune Earnings Call Transcript: Q1 2020

Babybock Apr. 27 at 10:32 AM

$ALT grabbing a few this morning to start my week off on the right foot.

0 · Reply

saad545 Apr. 27 at 10:31 AM

$ALT we will stay here until you cover and lose your money⬆️🔥

0 · Reply

GreenEnergy2022 Apr. 27 at 10:05 AM

$ALT Stocks goes up and down, 2,8 is not the end of the story here. Now we buy, and then we wait. Simplest thing in life

0 · Reply

lottomillions Apr. 27 at 10:05 AM

0 · Reply

OutlawBikerRR Apr. 27 at 9:52 AM

$ALT ARE WE HAPPY FOR 2.88$ ??

0 · Reply

Babybock Apr. 27 at 9:29 AM

$ALT

0 · Reply

AF5 Apr. 27 at 9:04 AM

$ALT

0 · Reply

PrecisionGuidanceNetwork Apr. 27 at 8:48 AM

$ALT biotech with sharp catalyst-driven volatility around major updates

0 · Reply

DragonAlgo Apr. 27 at 8:44 AM

0 · Reply

Rich1979 Apr. 27 at 7:41 AM

$ALT

0 · Reply

Lynxtail Apr. 27 at 6:56 AM

$ALT

0 · Reply

GreenEnergy2022 Apr. 27 at 6:48 AM

$ALT

0 · Reply

thaines1 Apr. 27 at 6:35 AM

$ALT

1 · Reply

Corpkcots Apr. 27 at 6:32 AM

$ALT

0 · Reply

DerStorch Apr. 27 at 6:18 AM

$ALT

0 · Reply

MakeAmericaSlimAgain Apr. 27 at 5:52 AM

$ALT interesting take https://www.linkedin.com/pulse/glp-1-market-has-split-most-people-havent-noticed-paul-healy--brrjf?utm_source=share&utm_medium=member_ios&utm_campaign=share_via

0 · Reply

BuddyBoy6975 Apr. 27 at 5:25 AM

$ALT Not an event where we’re gonna potentially hear what we wanna hear…. The news we want, Ph3 start, DOESN’T happen there…

0 · Reply

Chalutz Apr. 27 at 5:24 AM

$ALT why is someone always right not long retired with more interesting things to do that post here………? Weak dude……

0 · Reply

BuddyBoy6975 Apr. 27 at 5:08 AM

$ALT ALL I wanna hear is a Ph3 start date. ..! THAT’s when things START Plus Euro news. BIGLY …!!

0 · Reply

BuddyBoy6975 Apr. 27 at 5:03 AM

$ALT X-TREMELY

0 · Reply

StockDark Apr. 27 at 4:02 AM

$ALT As long as the stockwit sentiment is bullish this won’t move an inch. It has to turn to bearish for the stock to move.

1 · Reply

2MargaritaLunch Apr. 27 at 3:08 AM

$ALT

0 · Reply

Market Cap	370.80M
Revenue (ttm)	40,000.00
Net Income (ttm)	-88.09M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-220,225.00%
Debt to Equity Ratio	0.15

Volume	14,733,700
Avg Vol	3,925,564
Day's Range	N/A - N/A
Shares Out	130.11M
Stochastic %K	6%
Beta	0.34
Analysts	Strong Sell
Price Target	$18.00